97 results
6-K
EX-99.2
SNY
Sanofi
2 Feb 24
Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo
1:21pm
to Win Strategy. Under his leadership, our finance organization has been modernized into a team that supports our mission and execution of our
6-K
EX-99.5
SNY
Sanofi
20 Dec 23
Current report (foreign)
10:39am
and simplifying treatment delivery. This partnership and our donation of Fexinidazole Winthrop through Foundation S, reflect our mission to provide innovative
6-K
EX-99.1
SNY
Sanofi
27 Oct 23
Sanofi Enters Next Chapter of Play to Win Strategy
11:33am
Investment
Sanofi’s strategic mission is to transform the practice of medicine through breakthrough science that improves people’s lives. To that end
6-K
EX-99.3
SNY
Sanofi
20 Jun 23
Current report (foreign)
10:18am
shared is a problem halved and the Open Innovation Portal is part of our mission to unlock science to bring health in the hands of millions of consumers … mission to unlock science to empower consumers to take health in their hands, while also meeting sustainability goals of achieving carbon neutrality
6-K
EX-99.1
SNY
Sanofi
2 Jun 23
Approval of the financial statements for the fiscal year 2022
10:53am
and inflammation. He carried his mission with upmost integrity and commitment, in the best interest of the company. I thank the shareholders and the Board
6-K
EX-99.1
zyne1elwbpzet48t6feb
8 Aug 22
Sanofi and Innovent Biologics enter strategic
4:27pm
6-K
EX-99.1
vt11k 44y
28 Jul 22
Strong execution in Q2 drives full-year 2022 guidance upgrade and delivers rich R&D news flow in Immunology and Rare Disease
10:12am
6-K
EX-99.2
rkuq7elziasah8
28 Jul 22
Condensed Half-year Consolidated Financial Statements
6:17am
6-K
EX-99.1
ffu9bzyr cjfvwf2wdzz
8 Jul 22
Sanofi Global Health launches nonprofit Impact® brand for 30 medicines in low-income countries
11:01am
6-K
EX-99.2
syjtd 3eke9g6y4
13 Jun 22
FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
2:56pm
6-K
EX-99.1
mvs tpn2a8x2iizyr
29 Apr 22
Current report (foreign)
12:38pm
6-K
EX-99.1
e84brnk o60b
4 Apr 22
Distribution of Shares of Euroapi
11:21am
6-K
EX-99.1
gkp310n35g5egtqdc
22 Nov 21
Current report (foreign)
12:42pm
6-K
EX-99.1
t58babu1
10 Sep 21
Sanofi provides update on Phase 3 study evaluating rilzabrutinib for the treatment of pemphigus
3:23pm
SC TO-T
EX-99
83luhio 2y7jwv11
16 Aug 21
Third party tender offer statement
8:09am
6-K
EX-99.1
9k0uobh363
30 Jul 21
Current report (foreign)
4:01pm
6-K
EX-99.2
3gwie eel9p
29 Jul 21
Current report (foreign)
10:48am
6-K
EX-99.4
y4i494ibb1omc
13 Apr 21
Sanofi to invest in a leading-edge production site in Singapore; continues to strengthen its vaccines manufacturing capacities
2:56pm
6-K
EX-99.2
q8ehof
13 Apr 21
Sanofi to invest in a leading-edge production site in Singapore; continues to strengthen its vaccines manufacturing capacities
2:56pm